AstraZeneca has secured exclusive worldwide rights to Zegfrovy (sunvozertinib), Dizal Pharmaceutical’s oral EGFR inhibitor for EGFR exon 20 insertion non-small cell lung cancer, in a deal worth up to $1.5 billion. The agreement strengthens AstraZeneca’s EGFR-mutated lung cancer portfolio ahead of potential first-line expansion.
WuXi Biologics’ MFG8 facility in Hebei has successfully cleared a rigorous seven-day U.S. FDA Pre-License Inspection. This crucial WuXi Biologics FDA PLI Approval paves the way for the scaled commercial supply of a highly anticipated blockbuster autoimmune therapy, reinforcing the company’s unblemished 100% FDA PLI success rate and robust global quality standards.
Vertex Acquires Crinetics Pharmaceuticals under a definitive merger agreement, where Vertex will purchase all outstanding shares of Crinetics common stock for $85.00 per share in [Read More…]
Novartis has announced a definitive agreement to acquire UK-based biotechnology firm Myricx Bio for USD 1.1 billion upfront plus USD 400 million in milestones, gaining a breakthrough NMTi payload platform targeting solid tumors.
Roche has officially announced the launch of AXELIOS 1, a next-generation sequencing platform built on proprietary SBX technology, promising same-day whole-genome sequencing with unprecedented speed and accuracy.
Merck KGaA has entered into a definitive agreement to acquire Bio-Techne for US$73 per share in cash, representing an enterprise value of US$11.3 billion to strengthen its global leadership in high-growth life sciences markets.
Eli Lilly and Company has announced the successful completion of its acquisition of Centessa Pharmaceuticals plc, integrating a clinical-stage portfolio of orexin receptor 2 agonists to address severe sleep-wake disorders.
AbbVie and Apogee Therapeutics have announced a definitive $10.9 billion acquisition agreement. The transaction enhances AbbVie’s global immunology portfolio by adding advanced assets like zumilokibart (APG777) for atopic dermatitis and APG273 for asthma.
Pharmaceutical titan AbbVie is in advanced discussions to purchase anti-inflammatory biotech developer Apogee Therapeutics for $10.9 billion in cash, marking its most significant bolt-on transaction since 2019.
Novo Nordisk A/S has confirmed an IT security breach involving unauthorized access to limited internal systems and data exfiltration. Core operations remain unaffected.
